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STRUCTURAL CHARACTERIZATION AND FUNCTIONAL
RELEVANCE
Sebastian Kuhna, Markus Ladweina, Ulrich-Frank Papeb, Werner
W. Frankeb, Margot Zo¨llera. aDepartment of Tumor Progression and
Tumor Defense, Deutsches Krebsforschungszentrum, Heidelberg, Germany;
bDepartment of Cell Biology, Deutsches Krebsforschungszentrum,
Heidelberg, Germany.
Background: The homotypic cell–cell adhesion molecule EpCAM
is a transmembrane protein expressed on the surface of nearly all
epithelia. Originally it was identified as a tumor specific antigen
overexpressed in various types of carcinomas. Claudin-7 is a
transmembrane protein known as one of the major components
of tight junctions. We recently demonstrated a direct interaction
between EpCAM and Claudin-7 on several carcinomas and non-
transformed tissue of the gastrointestinal tract that was not
restricted to tight junctions.
Methods: The ectopic expression of EpCAM and Claudin-7 in
HEK293T cells was used to characterize the interaction of both
proteins and to analyze the influence of Claudin-7 on different
known biological properties of EpCAM like oligomerisation or
association of EpCAM with glycolipid-enriched membrane micro-
domains (GEM).
Results: The binding site of EpCAM for Claudin-7 could be
restricted to the extracellular cystein-poor region or the trans-
membrane domain of EpCAM. Interestingly the oligomerisation
of EpCAM is decreased in the presence of Claudin-7. Furthermore,
both EpCAM and Claudin-7 are recovered from GEMs enriched in
tetraspanins, whereby Claudin-7 is required for the EpCAM
recruitment into GEMs.
Conclusions: Though the functional consequences of the inter-
action of EpCAM with Claudin-7 remain to be explored both
observations offer starting points for an understanding of the
functional relevance of this complex. First, by interfering with
the oligomeric state of EpCAM Claudin-7 could well influence
EpCAM mediated cell–cell-adhesion properties. Second, by
recruiting of EpCAM to GEM associated signaling platforms Clau-
din-7 might facilitate the induction of downstream signaling cas-
cades, yet to be identified.
doi:10.1016/j.ejcsup.2006.04.098
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Jeggoc, Jiri Bartekd, Alwin Kra¨mera. aClinical Cooperation Unit for
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Background: One of the most common properties of cancer is
genomic instability. Possible causes include centrosome aberra-tions and defects of the DNA damage response (DDR). ATR-Sec-
kel syndrome and ataxia-teleangiectasia are autosomal
recessive disorders associated with hematologic malignancies,
which share the feature of genomic instability and are caused
by DDR defects, namely by a hypomorphic ATR mutation and
inactivating ATM mutations, respectively. A downstream sub-
strate of both ATM and ATR is the nuclear checkpoint kinase
Chk1, which we have recently shown to localize to interphase
centrosomes and thereby negatively regulate entry into mitosis
by preventing premature activation of cyclin B-Cdk1 [Nat Cell
Biol 2004;6:884–91].
Methods: We assessed centrosomal Chk1 by immunofluores-
cence in different fibroblast cell lines with and without DNA-
damaging treatment.
Results: DNA damage by ultraviolet radiation or hydroxyurea
enhanced the centrosomal localization of Chk1. In fibroblasts
derived from ATR-Seckel or ataxia-teleangiectasia patients, this
DNA damage-dependent centrosomal accumulation of Chk1
was more pronounced as compared to control fibroblasts. Accord-
ingly, this phenotype is not dependent on ATR or ATM.
Conclusion: Centrosomal accumulation of Chk1 in response to
DNA damage leading to G2/M arrest may contribute a novel regu-
latory mechanism to the DDR armamentarium.
doi:10.1016/j.ejcsup.2006.04.099
P40. THE HUMAN IIIb-mRNA SPLICE-VARIANT OF THE
FGF-RECEPTOR-1(FGFR1) REDUCES THE TRANSFORMING
POTENTIAL OF PANCREATIC CARCINOMA CELL LINES
IN VITRO AND IN VIVO
M. Thiere, Z. Liu, D. Henne-Bruns, M. Kornmann. Department of
General Surgery, University of Ulm, Germany.
Background: Fibroblast growth factors (FGFs) and their specific
receptors (FGFRs) are involved in several biological processes like
angiogenesis and cell proliferation. We showed that the IIIc-vari-
ant of the human FGFR1 is able to induce the transforming poten-
tial in TAKA-1 ductal pancreatic cells. We also demonstrated that
the now completely cloned human FGFR1-IIIb-variant is a func-
tional FGFR, which reduces growth of TAKA-1 ductal and PANK-1
pancreatic carcinoma cells. The aim of this study was to investi-
gate the influence of FGFR1-IIIb-expression on transforming
potential of pancreatic carcinoma cells.
Methods: Colony-forming rate, cell mobility in real-time-micros-
copy and ability of invasion in a Boyden-chamber were assessed
in vitro. Tumor formation rate of either PANC-1 control clones
(PN5, PN6) or FGFR1-IIIb expressing clones was monitored after
establishment in nude mice.
Results: FGFR1-IIIb expressing clones showed minor growth and
lower colony forming rate of >70% compared to control clones
and a significant reduction of cell mobility in vitro. Ability of inva-
sion was lowered to >75%. In vivo 14 of 16 (PF4) and 16 of 24 (PF40)
FGFR1-IIIb-clone injected areas showed solid tumors within 6
weeks. By comparison almost all areas being injected with control
clones formed solid tumors (8 of 8 for PN5, 22 of 24 for PN6). Total
amount of solid tumors as well as volume increase of the FGFR1-
IIIb expressing tumors was reduced.
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tumor growth in vitro and in vivo and prolong overall survival.
doi:10.1016/j.ejcsup.2006.04.100
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PROSTATE CANCER AFTER SHORT TERM ANTIHORMONAL
THERAPY
K. Beckera, C.G. Sauera, H. Zentgrafb, R. Grobholza. aPathologisches
Institut, Universita¨tsklinikum Mannheim, Heidelberg, Germany; bAbt.
ATV DKFZ, Heidelberg, Germany.
Background: PTEN is an important phosphatase, suppressing
the phosphatidylinositol-3-kinase/Akt pathway which induces
apoptosis. p27kip1 binds to cyclin-E/Cdk2 and prevents mitosis.
The inactivation of the tumor suppressor genes has been associ-
ated with many different types of cancer including the prostatic
carcinoma (PCa). In this study we investigated the influence of
an antihormonal treatment on the expression of PTEN and
p27kip1 in PCa.
Methods: 82 prostate cancer patients treated with antiandro-
gens or LH-RH analogs or a combination therapy between 1 and
77 weeks (mean 9.7 ± 1.2) were included in this study. The expres-
sion of PTEN and p27kip1 were analyzed by immunhistochemistry
and an immunreactive score. The results were compared with 183
untreated cases of a previous study.
Results: PTEN expression levels correlated with the duration of
antihormonal therapy: significantly more PTEN positive cases
were found after 3 weeks antihormonal therapy (p = 0.0003).
PTEN-expression compared to untreated tumors showed a signif-
icantly stronger PTEN-expression in treated tumors (p = 0.03). A
nuclear expression of p27kip1 was more frequent in tumors after
4 weeks of treatment compared to tumors treated less than 4
weeks (p = 0.015).
Conclusions: Both PTEN and p27kip1 expression was increased
after 4 weeks of antihormonal treatment. This fact might indicate
an early stress reaction of the tumor cells due to the androgen-
deprivation therapy.
doi:10.1016/j.ejcsup.2006.04.101
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A KEY COMPONENT OF ESTRADIOL SIGNALLING PATHWAY
Grisouard Jean, Medunjanin Senad, Strauth Stephanie, Hermani
Alexander, Mayer Doris. German Cancer Research Centre (DKFZ),
Research Group Hormones and Signal Transduction, Heidelberg,
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Background: GSK3beta is involved in the control of gene expres-
sion via the regulation of transcription factors, including estrogen
receptor alpha (ERalpha). Recently, we discovered involvement of
GSK3beta in estrogen-independent and estrogen-dependent acti-
vation of ERalpha, respectively.1,2 While phosphorylation of ERal-
pha appears to be crucial for its activation, the impact ofGSK3beta on the estrogen-dependent regulation of ERalpha func-
tion and activity remains to be clarified.
Methods: Phosphorylation of ERalpha by GSK3beta was analysed
by in vitro kinase assays. Thereafter, the effects of GSK3 inhibitors
on ERalpha phosphorylation and activation were analysed in
breast cancer cells using Western blot and luciferase reporter
assays. Further experiments using siRNA technology and trans-
fection of cells with GSK3beta mutants were performed to inves-
tigate the effects of GSK3beta regarding ERalpha signalling
pathway.
Results: In vitro kinase assays first depicted that GSK3beta phos-
phorylated ERalpha at Ser-118. Moreover, the addition of a GSK3
inhibitor (LiCl) on MCF-7 cells in culture stimulated with estradiol
(E2) led to a decrease in Ser-118 phosphorylation and to an inhibi-
tion of ERalpha-controlled luciferase activity. In agreement with
the previous observations, the knock-down of GSK3 by use of
siRNA resulted in decreased basal and E2-induced ERalpha phos-
phorylation at Ser-118 as well as in reduced luciferase activity.
Conclusion: We suggest that GSK3beta plays an important role
in the estrogen-dependent regulation of ERalpha function and
activity.
doi:10.1016/j.ejcsup.2006.04.102
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Background: ErbB-receptors/ligands are involved in several can-
cers. Plasma cells expressing the heparin-sulphate proteoglycan
(HSPG) syndecan-1 (CD138) attach heparin-binding growth fac-
tors.1 The aim of this study is to identify new targets in the ther-
apy of multiple myeloma (MM).
Methods: Samples of 65 patients (CD138-purified MM-cells (MMC)
and bone-marrow-microenvironment (BMME)), 7 normal bone-
marrow-plasma-cell-samples (BMPC) and 20 human-myeloma-
cell-lines were studied. The expression of the 4 ErbB-receptors/
ligands on MMC and BMME will be assessed by real-time RT-PCR
and Affymetrix U133 A+B DNA-microarrays. BMME-cells from
MM-patients were exposed to PD169540 (a pan-ErbB-inhibitor)
and IRESSA (ErbB1-specific).
Results: ErbB1 and ErbB2 are expressed by BMPC, MMC and the
BMME. ErbB3 and ErbB4 are expressed by a subgroup of MMC. 7/
10 ErbB-ligands are expressed by MMC and/or the BBME. Myeloma
cell growth is stimulated by the 3 ErbB-ligands that are able to
attach HSPG (i.e amphiregulin, HB-EGF and neuregulin-1) via
binding to syndecan-1. PD169540 and IRESSA induced apoptosis
of primary MMC from 10/14 and 4/14 patients in vitro,
respectively.1,2
